Non-alcoholic Fatty Liver Disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

Non-alcoholic Fatty Liver Disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112025A6575

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Non-alcoholic Fatty Liver Disease- Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence

5 Non-alcoholic Fatty Liver Disease- Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Non-alcoholic Fatty Liver Disease- Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)

8 Non-alcoholic Fatty Liver Disease- Treatment Algorithm, Guidelines, and Medical Practices
8.1 Non-alcoholic Fatty Liver Disease Guidelines, Management and Treatment
8.2 Non-alcoholic Fatty Liver Disease Treatment Algorithm

9 Non-alcoholic Fatty Liver Disease- Unmet Needs

10 Non-alcoholic Fatty Liver Disease- Key Endpoints of Treatment

11 Non-alcoholic Fatty Liver Disease- Marketed Products
11.1 List of Non-alcoholic Fatty Liver Disease Drugs (Off-Label/Marketed) Across the Top 7 Markets
11.1.1    Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Non-alcoholic Fatty Liver Disease- Pipeline Drugs
12.1 List of Non-alcoholic Fatty Liver Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Oltipraz - PharmaKing
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Cotadutide - AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Lanifibranor - Inventiva Pharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Pemafibrate - Kowa Pharmaceutical
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Clesacostat - Pfizer
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.

13. Non-alcoholic Fatty Liver Disease- Attribute Analysis of Key Marketed and Pipeline Drugs

14 Non-alcoholic Fatty Liver Disease- Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1    Non-alcoholic Fatty Liver Disease- Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2    Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1    Non-alcoholic Fatty Liver Disease- Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2    Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3    Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Non-alcoholic Fatty Liver Disease- Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2    Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3    Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Non-alcoholic Fatty Liver Disease- Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2    Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3    Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Non-alcoholic Fatty Liver Disease- Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2    Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3    Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Non-alcoholic Fatty Liver Disease- Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2    Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3    Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Non-alcoholic Fatty Liver Disease- Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2    Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3    Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1    Non-alcoholic Fatty Liver Disease- Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2    Non-alcoholic Fatty Liver Disease- Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3    Non-alcoholic Fatty Liver Disease- Access and Reimbursement Overview

15 Non-alcoholic Fatty Liver Disease- Recent Events and Inputs From Key Opinion Leaders

16 Non-alcoholic Fatty Liver Disease Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats

17 Appendix

Non-alcoholic Fatty Liver Disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials